Renal cell carcinoma (RCC) is one of the most prevalent urological malignancies worldwide[@b1][@b2]. The incidence of RCC, a highly aggressive disease, has steadily increased over the years. Approximately 30% of patients have metastases at first diagnosis, and another 20% of RCC patients with clinically localized disease will develop metastasis even after curative nephrectomy[@b3]. Although novel target therapies have been developed, most metastatic RCCs still eventually cause death[@b4]. Prediction models identifying patients with poor prognosis, who may benefit from early systematic therapy, are greatly needed. To date, the tumor, node, and metastasis (TNM) staging system is a widely used RCC prognostic predictor. However, it is inferior in accurately predicting the prognosis of RCC patients with diverse and complicated tumor backgrounds[@b5]. Therefore, novel biomarkers that can stratify patients with poor prognosis should be identified to precisely guide clinical decisions.

Ki-67, a proliferation marker that is expressed during the cell cycles of G1, S, G2, and M stages, except G0, is usually detected by immunohistochemical (IHC) staining[@b6]. Its strict association with cell proliferation and its co-expression with other well-known markers of proliferation indicate a pivotal role in cell division. Several studies recently reported that Ki-67 expression is associated with poor prognosis in several types of cancer[@b7][@b8][@b9][@b10]. However, the role of Ki-67 in the prognosis of RCC remains inconsistent. Ki-67 was considered an unfavorable prognostic marker in RCC in many studies[@b11][@b12][@b13][@b14], but some studies reported that Ki-67 expression is prognostically irrelevant in RCC patients[@b15][@b16]. To obtain a more precise evaluation of the prognostic and clinicopathological value of Ki-67 expression in RCC, we performed a systematic review and meta-analysis to evaluate the prognostic value of Ki-67 quantitatively and explore the associations of Ki-67 with the clinicopathological features of RCC.

Results
=======

Search Results
--------------

Our search strategy initially identified 1540 articles from the primary literature search. A total of 502 duplicate reports were excluded. After screening the titles and abstracts, 993 articles were excluded for various reasons such as non-human studies, letters, case reports, meeting records, reviews, and other obvious irrelevant studies. The remaining 45 articles were evaluated in full text. To avoid the heterogeneity caused by the detection method, studies without IHC evaluation were excluded. The remaining articles were further excluded for several reasons, such as no data available (hazard ratio \[HR\] and 95% confidence interval \[CI\]), low-quality studies[@b17], and duplicate publication. Finally, 20 articles published from 2000 to 2016 with 5,398 patients satisfied the criteria for meta-analysis[@b11][@b12][@b13][@b14][@b15][@b16][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31]. A flowchart of the study selection process is shown in [Fig. 1](#f1){ref-type="fig"}.

Characteristics of Studies
--------------------------

The main characteristics of the 20 studies are summarized in [Table 1](#t1){ref-type="table"}. Patients in these studies were all diagnosed with RCC with different tumor types and received radical or partial nephrectomy. Seven studies originated from the United States, three were from Finland, two were from Germany, two were from China, one was from France, one was from Japan, one was from Norway, one was from Italy, one was from Portugal, and one was from the United Kingdom. Among the studies, five studies were performed to analyze overall survival (OS), 11 studies were conducted to investigate cancer-specific survival (CSS), and six studies reported disease-free survival (DFS). Various clinicopathological data were reported in eight studies (TNM stage in four studies, pathological T stage in eight studies, metastasis in five studies, and Fuhrman grade in eight studies). All studies applied IHC staining to investigate Ki-67 expression. Positive Ki-67 expression was defined using different cutoff values among various studies, so we classified all the cases according to their original studies (positive or negative staining).

Meta-Analysis
-------------

Our meta-analysis demonstrated that high Ki-67 expression in RCC was associated with poor OS (fixed-effect model, HR = 1.95; 95% CI: 1.44--2.64; p \< 0.001; *I*^*2*^ = 0.0%, p = 0.594; [Fig. 2A](#f2){ref-type="fig"}), CSS (fixed-effect model, HR = 1.67; 95% CI: 1.47--1.89; p \< 0.001; *I*^*2*^ = 2.7%, p = 0.417; [Fig. 2B](#f2){ref-type="fig"}), and DFS (fixed-effect model, HR = 2.56; 95% CI: 1.79--3.67; p \< 0.001; I^2^ = 0.0%, p = 0.598; [Fig. 2C](#f2){ref-type="fig"}). To explore the source of heterogeneity, meta-regression analysis on CSS was conducted by ethnicity, tumor extent at time of diagnosis, counting method, cutoff of staining, follow up time. The results showed that ethnicity (p = 0.889), tumor extent at time of diagnosis (p = 0.415), counting method (p = 0.858), cutoff of staining (p = 0.305), and follow up time (p = 0.467) were not significant contributors to heterogeneity. Furthermore, subgroup analysis stratified by ethnicity, tumor extent at time of diagnosis, histopathological subtype, counting method, cutoff of staining, and follow up time was also performed. With regard to ethnicity, high Ki-67 expression was correlated with poor OS (HR = 1.95; 95% CI: 1.44--2.64; p \< 0.001), CSS (HR 1.67; 95% CI: 1.47--1.89; p \< 0.001), and DFS (HR = 2.63; 95% CI: 1.73--4.01; p \< 0.001) in Caucasian patients, as well as with poor DFS (HR = 2.38; 95% CI: 1.18--4.80; p = 0.015) but not with CSS (HR = 1.88; 95% CI: 0.41--8.67; p = 0.417) in Asian patients ([Table 2](#t2){ref-type="table"}). Regarding the tumor extent, high Ki-67 expression was associated with poor OS (HR 2.01; 95% CI: 1.46--2.77; p \< 0.001) and CSS (HR 1.80; 95% CI: 1.52--2.31; p \< 0.001) but not with DFS (HR = 2.11; 95% CI: 0.74--6.50; p = 0.178) for all stages of RCC; with poor DFS (HR = 2.63; 95% CI: 1.79--3.85; p \< 0.001) but not with OS (HR 1.40; 95% CI: 0.52--3.76; p = 0.504) and CSS (HR = 2.29; 95% CI: 0.85--6.19; p = 0.104) for localized RCC; and with poor CSS (HR = 1.49; 95% CI: 1.22--1.82; p \< 0.001) for metastatic RCC. For histopathological subtype, high Ki-67 expression was correlated with poor CSS (HR = 1.67; 95% CI: 1.47--1.89; p \< 0.001) and DFS (HR = 3.66; 95% CI: 2.00--6.72; p \< 0.001) for ccRCC. With respect to counting method, high Ki-67 expression was correlated with poor OS (HR = 1.86; 95% CI: 1.22--2.82; p = 0.004), CSS (HR 1.66; 95% CI: 1.44--1.90; p \< 0.001), and DFS (HR = 2.57; 95% CI: 1.73--3.79; p \< 0.001) for eyeball counting, as well as with poor OS (HR = 2.05; 95% CI: 1.32--3.19; p = 0.001) and CSS (HR = 1.73; 95% CI: 1.26--2.38; p = 0.001) for formal counting. In the cutoff of staining subgroup analysis, high Ki-67 expression was correlated with poor DFS (HR = 7.18; 95% CI: 1.91--26.99; p = 0.004) but not with CSS (HR = 1.26; 95% CI: 0.66--2.41; p = 0.476) when the cutoff value was less than 10%. Studies with a cutoff value greater than or equal to 10% showed that high Ki-67 expression was associated with poor OS (HR = 1.86; 95% CI: 1.22--2.82; p = 0.004), CSS (HR = 1.90; 95% CI: 1.45--2.49; p \< 0.001), and DFS (HR = 2.36; 95% CI: 1.62--3.43; p \< 0.001). Additionally, high Ki-67 expression was associated with poor CSS (HR 1.59; 95% CI: 1.38--1.84; p \< 0.001) and DFS (HR = 2.45; 95% CI: 1.54--3.91; p \< 0.001) in patients with follow up time less than 60 months; with poor OS (HR = 1.95; 95% CI: 1.44--2.64; p \< 0.001), CSS (HR 1.93; 95% CI: 1.22--3.03; p = 0.005), and DFS (HR = 2.73; 95% CI: 1.55--4.82; p = 0.001) in patients with follow up time greater than or equal to 60 months.

In the comprehensive analyses of the role of Ki-67 expression in RCC as a biomarker, we investigated the relationship between elevated Ki-67 expression and clinicopathological characteristics. As shown in [Table 3](#t3){ref-type="table"}, high Ki-67 expression was significantly related to TNM stage (III/IV vs. I/II: risk ratio \[RR\] 2.03; 95% CI: 1.68--2.44; p \< 0.001), pathological T stage (T3/T4 vs. T1/T2: RR = 1.67; 95% CI: 1.35--2.06; p \< 0.001), metastasis (yes vs. no: RR = 2.15; 95% CI: 1.77--2.62; p \< 0.001), and Fuhrman grade (III/IV vs. I/II: RR = 1.77; 95% CI: 1.20--2.60; p = 0.004). Some significant interstudy heterogeneity was observed in pathological T stage and Fuhrman grade, but analyses on TNM stage and metastasis did not exhibit significant heterogeneity.

Sensitivity Analysis
--------------------

A sensitivity analysis was conducted by sequential omission of individual studies. Results are shown in [supplementary materials](#S1){ref-type="supplementary-material"} (Sensitivity analysis). The pooled HR of OS, CSS, and DFS were not significantly changed, suggesting the robustness of the results.

Publication Bias
----------------

Begg's and Egger's tests, as well as funnel plots, were conducted to estimate publication bias in the present meta-analysis. As shown in [Fig. 3](#f3){ref-type="fig"}, the funnel plots indicated that the included studies had no evident asymmetry. Furthermore, the results from Begg's test (P value) and Egger's test (intercept with corresponding 95% CI, P value) for the included studies assessing the survival outcomes were P~Begg's~ = 0.806, intercept 0.51 with 95% CI: −2.97 to 3.99, P~Egger's~ = 0.673 (OS); P~Begg's~ = 0.161, intercept 0.99 with 95% CI: −0.07 to 2.06, P~Egger's~ = 0.065 (CSS); and P~Begg's~ = 0.133, intercept 2.02 with 95% CI: −1.19 to 5.23, P~Egger's~ = 0.156 (DFS). These findings suggested that significant publication bias did not exist in our meta-analysis.

Discussion
==========

First described in 1991 by Gerdes *et al*.[@b32], Ki-67, a nuclear protein, is a famous marker of cell proliferation. It is expressed throughout the cell cycle in proliferating but not quiescent (G0) cells, so it has been used as a proliferation marker in many cancers. Recently, Ki-67 has drawn increasing attention as an attractive prognostic prediction marker and potential therapeutic target in malignant neoplasms. Several studies suggested that Ki-67 is significantly associated with the prognosis of bladder cancer, breast cancer, lung cancer, upper urinary tract urothelial carcinomas, cervical cancer, and lymphoma[@b6][@b9][@b33][@b34][@b35][@b36]. However, the prognostic and clinicopathological values of Ki-67 remain ambiguous in RCC. Therefore, we conducted this meta-analysis to resolve the remaining controversy and reach a reasonable conclusion.

In this study, we focused exclusively on validating Ki-67 IHC expression and evaluated the prognostic values of Ki-67 IHC expression in RCC. We concluded that high Ki-67 expression predicted unfavorable prognosis for patients with RCC. In particular, RCC patients with high Ki-67 expression exhibited poor OS, CSS, and DFS. Subgroup analysis revealed the following results. (1) In terms of ethnicity, high Ki-67 expression was correlated with poor OS, CSS, and DFS in Caucasian patients, as well as with poor DFS but not significantly with CSS in Asian patients. (2) Regarding the tumor extent, high Ki-67 expression was associated with poor OS and CSS but not significantly with DFS for all stages of RCC; with poor DFS but not significantly with OS and CSS for localized RCC; and with poor CSS for metastatic RCC. (3) For histopathological subtype, high Ki-67 expression was correlated with poor CSS and DFS for ccRCC. (4) In the cutoff of staining subgroup analysis, high Ki-67 expression was correlated with poor DFS but not significantly with CSS when the cutoff value was less than 10%. Studies with a cutoff value greater than or equal to 10% showed that high Ki-67 expression was associated with poor OS, CSS, and DFS. Subgroup analysis revealed that RCC patients with high Ki-67 expression presented a relatively unfavorable survival outcome, even though some association did not reach statistical significance. The absence of a significant association was possibly due to the relatively limited studies in the subgroups.

Our results also suggested that RCC patients with high Ki-67 expression were likely to have a higher TNM stage, pathological T stage, positive metastasis, and a higher Fuhrman grade. The biological mechanism of Ki-67 may partly explain its prognostic and clinicopathological significance in patients with RCC. Ki-67 is a well-known cell proliferation biomarker in many tumors and plays a critical role in mitosis by regulating chromatin recombinant. Ki-67 has been considered a good molecular surrogate of the aggressive behavior and therapy response for survival outcome assessment in several cancers including RCC[@b28]. In addition to the commonly applied proliferative activity marker, Ki-67 may be associated with promotion of epithelial-to-mesenchymal transition (EMT)[@b37][@b38]. EMT induction is a key process for development and progression of malignant tumors.

This study is the first comprehensive analysis on the associations between Ki-67 expression and prognostic and clinicopathological significance in patients with RCC, but several limitations should be acknowledged. First, all included studies measured Ki-67 expression via IHC, but the criteria to determine the positive or negative expression of Ki-67 were inconsistent in different studies, which may potentially contribute to heterogeneity. Therefore, a more unified standard should be defined in the future. Second, a remarkable heterogeneity of studies was observed in certain categories of analysis. The heterogeneity was probably caused by differences in factors such as the patients' characteristics (ethnicity, nationality, gender, age, and tumor stage and grade), variation in cutoff values for Ki-67 expression, and different durations of follow up. Third, relatively few studies were extracted in some subgroup analyses, which might render premature results. With more eligible studies published in the future, an update is necessary to achieve a more reliable result. Finally, research with positive results is potentially more likely to be submitted and published than work with negative results, which could cause publication bias[@b39], although this bias was not detected in the present analysis.

To conclude, despite the limitations listed above, this meta-analysis suggested the prognostic and clinicopathological importance of Ki-67 expression in RCC. The results demonstrated that high Ki-67 expression was associated with poor prognosis and advanced clinicopathological features, which could potentially serve as risk stratification markers and even therapeutic targets in RCC. However, more large-scale, multicenter prospective studies with standardized methods and long-term follow up are needed to verify our results.

Methods
=======

Search Strategy
---------------

This meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)[@b40].

A systematic literature search was performed in the electronic databases PubMed, Web of Science, and Embase on April 20, 2016 using the following search strategy: ("Ki67" or "Ki-67" or "MIB-1") and ("carcinoma" or "neoplasm" or "tumor" or "cancer" or "malignancy") and ("kidney" or "renal") and ("prognosis" or "prognostic" or "survival" or "outcome" or "mortality"). Moreover, we manually searched the reference lists of relevant literature.

Selection Criteria
------------------

Studies were included based on the following criteria: (1) the association of Ki-67 with the prognostic value in RCC should be described, (2) studies detected Ki-67 protein expression by IHC, and (3) studies reported survival outcomes (OS, CSS, or DFS) with HR and 95% CI. Exclusion criteria were as follows: (1) non-English papers; (2) case reports, letters, commentaries, meeting records, or review articles; (3) the study focused on animal models or cancer cells; (4) the study investigated the survival outcomes of RCC by the combination of Ki-67 with other IHC marker(s); (5) the study did not analyze Ki-67 protein expression, clinical features, and survival outcome; and (6) the study lacked sufficient data for obtaining HR and 95% CI. All evaluations were independently performed by three individual researchers to ensure the accurate inclusion of studies. For duplicate studies, we only retrieved the most informative and recent studies for further analyses.

Data Extraction
---------------

The data of the eligible studies were extracted independently with a predefined form. Discrepancies in data extraction were resolved by discussion. The following data were extracted: surname of the first author, publication year, origin of the studied population, study design, extent of tumor, histopathological subtype, number of patients, gender, patient's age, cutoff value, follow-up time, and effect estimates, namely, HR of Ki-67 expression for OS, CSS, or DFS, as well as their 95% CI ([Table 1](#t1){ref-type="table"}). If the HR and 95% CI were not directly available, we calculated HRs and their 95% CI based on the methods reported by Tierney *et al*.[@b41].

Quality Assessment
------------------

The quality of the included studies was evaluated using the Newcastle--Ottawa scale, which was recommended by the Cochrane Non-Randomized Studies Methods Working Group[@b17]. Each study can be assessed by eight methodology items with a score ranging from 0 to 9. The high scores indicated high quality. We considered studies with scores of 6 or more as high quality for the meta-analysis. Only high-quality studies were included in further analysis to assure the quality of this meta-analysis.

Statistical Analysis
--------------------

Pooled HR and RR with 95% CI were used to evaluate the association of Ki-67 expression with RCC prognosis and clinicopathological characteristics, respectively. An observed HR \> 1 indicated poor prognosis for patients with high Ki-67 expression. An observed RR \> 1 implied advanced clinicopathological characteristics in the high Ki-67 expression group. A heterogeneity test of pooled HR and RR was conducted using Cochran's Q test and Higgins I-squared statistic. A P value of less than 0.1 was considered significant. The I^2^ values \>50% is considered as a measure of severe heterogeneity[@b42]. A random-effect model was used when heterogeneity was observed (p \< 0.1); otherwise, a fixed-effect model was used. The reasons for inter-study heterogeneity were also explored by using meta-regression analysis. To obtain a more precise evaluation of heterogeneity, we only performed meta-regression analysis on CSS which had sufficient included studies (n ≥ 10). Publication bias was assessed by funnel plot visual inspection and then statistically evaluated by Begg's[@b43] and Egger's tests[@b44]. The statistical processes were performed by Stata 12.0 software (StatCorp, College Station, TX, USA), and p \< 0.05 was considered statistically significant.
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###### Characteristics of eligible studies in the meta-analysis.

  Study                 Year   Country    Study design   Tumor extent^a^   Histopathological subtype   Case number   Gender (M/F)          Age (years)          Counting method       Cut-off staining       follow-up (months)   Survival analysis   Quality score\*
  -------------------- ------ ---------- -------------- ----------------- --------------------------- ------------- -------------- --------------------------- ----------------- -------------------------- -------------------- ------------------- -----------------
  Rioux-Leclercq        2000    France    Cohort study      all-stage                ccRCC                 73           47/26                Mean 64                eyeball                 20%                      52                  CSS                 8
  Yuba                  2001    Japan     Cohort study      all-stage                ccRCC                 52            43/9               Mean 58.4               eyeball                 5.6%                     39                  CSS                 7
  Cheville              2002     USA      Cohort study      localized                ccRCC                 232            NA                   NA               formal counting              5%                     126                  CSS                 8
  Bui                   2004     USA      Cohort study      all-stage                ccRCC                 224          149/75              Mean 61.5           formal counting             10%                      34                  CSS                 8
  Kim                   2004     USA      Cohort study      all-stage                ccRCC                 318         215/103               Mean 61                eyeball                 15%                      28                  CSS                 8
  Lehmann               2004   Germany    Cohort study      localized                ccRCC                 48           27/21               Median 63               eyeball                  6%                      91                  DFS                 6
  Dudderidge            2005      UK      Cohort study      localized          ccRCC + non-ccRCC           176          120/56              Mean 63.7               eyeball                 12%                      44                  DFS                 8
  Kim                   2005     USA      Cohort study     metastatic                ccRCC                 150          107/43               Mean 59                eyeball                  NA                     14.8                 CSS                 6
  Pinto                 2005   Portugal   Cohort study      all-stage          ccRCC + non-ccRCC           64           34/30               Mean 61.6               eyeball                 10%                      86                  OS                  6
  Kankuri               2006   Finland    Cohort study      localized          ccRCC + non-ccRCC           37           18/19               Mean 62.2               eyeball                 10%                      76                OS,DFS                6
  Tollefson             2007     USA      Cohort study      all-stage                ccRCC                 741         475/266      358/383^b^ (≥65 y/\<65 y)       eyeball       ≥50 positive cells/mm^2^         \>39.6                CSS                 9
  Gontero               2008    Italy     Cohort study      all-stage              non-ccRCC               46            37/9         28/18 (≥60 y/\<60 y)          eyeball                 14%                     84.5                 OS                  8
  Parker                2009     USA      Cohort study      all-stage                ccRCC                 634         413/221       312/322 (≥65 y/\<65 y)         eyeball       ≥50 positive cells/mm^2^           NA                  CSS                 8
  Zubac                 2009    Norway    Cohort study      all-stage                ccRCC                 172          95/77               Mean 66.6           formal counting             10%                     68.4                 CSS                 8
  Kankuri-Tammilehto    2010   Finland    Cohort study      all-stage          ccRCC + non-ccRCC           57             NA                 Mean 61                eyeball                 10%                    \>100                 OS                  6
  Weber                 2013   Germany    Cohort study      localized                ccRCC                 132          80/52              Median 63.5              eyeball                 15%                    122.4                 CSS                 8
  Gayed                 2014     USA      Cohort study      localized                ccRCC                 401         239/162              Median 58               eyeball                 10%                      22                DFS,CSS               8
  Teng                  2014    China     Cohort study      localized                ccRCC                 378         272/106              Mean 53.4                 NA                    50%                      60                  DFS                 8
  Zheng                 2014    China     Cohort study      all-stage          ccRCC + non-ccRCC          1239         858/381                53.9                  eyeball                 15%                     56.8                 DFS                 8
  Virman                2016   Findland   Cohort study      all-stage          ccRCC + non-ccRCC           224          132/92              Median 65           formal counting       Median staining               64.8                 OS                  9

ccRCC: clear cell renal cell carcinoma; OS: overall survival; CSS: cancer-specific survival; DFS: disease-free survival; NA: not available.

^a^Reported at time of diagnosis.

^b^358 patients ≥ 65 years, and other 383 patients \< 65 years.

\*The quality of the included studies was evaluated using the Newcastle--Ottawa scale.

###### Subgroup analysis of pooled HR for RCC patients with Ki-67 overexpression.

  Outcome                     Subgroup     Studies    Pooled HR    95% CI    P Value   Model   Heterogeneity *I*^*2*^ (%)
  --------------------------- ----------- --------- ------------- --------- --------- ------- ----------------------------
  OS                          Ethnicity                                                       
   Caucasian                  5             1.95     1.44--2.64    \<0.001    fixed      0               0.594
   Asian                      0               ─           ─           ─         ─        ─                 ─
  Tumor extent                                                                                
   all-stage                  4             2.01     1.46--2.77    \<0.001    fixed      0               0.510
   localized                  1             1.40     0.52--3.76     0.504       ─        ─                 ─
   metastatic                 0               ─           ─           ─         ─        ─                 ─
  Histopathological subtype                                                                   
   ccRCC                      0               ─           ─           ─         ─        ─                 ─
  Counting method                                                                             
   eyeball counting           4             1.86     1.22--2.82     0.004     fixed      0               0.443
   formal counting            1             2.05     1.32--3.19     0.001     fixed      ─                 ─
  Cutoff of staining                                                                          
   \<10%                      0               ─           ─           ─         ─        ─                 ─
   ≥10%                       4             1.86     1.22--2.82     0.004     fixed      0               0.443
  Follow up (month)                                                                           
   \<60                       0               ─           ─           ─         ─        ─                 ─
   ≥60                        5             1.95     1.44--2.64    \<0.001    fixed      0               0.594
  CSS                         Ethnicity                                                       
   Caucasian                  10            1.67     1.47--1.89    \<0.001    fixed    12.2              0.331
   Asian                      1             1.88     0.41--8.67     0.417       ─        ─                 ─
  Tumor extent                                                                                
   all-stage                  7             1.80     1.52--2.13    \<0.001    fixed      0               0.676
   localized                  3             2.29     0.85--6.19     0.104    random    52.8              0.120
   metastatic                 1             1.49     1.22--1.82    \<0.001      ─        ─                 ─
  Histopathological subtype                                                                   
   ccRCC                      11            1.67     1.47--1.89    \<0.001    fixed     2.7              0.417
  Counting method                                                                             
   eyeball counting           8             1.66     1.44--1.90    \<0.001    fixed    13.7              0.323
   formal counting            3             1.73     1.26--2.38     0.001     fixed     4.8              0.350
  Cutoff of staining                                                                          
   \<10%                      2             1.26     0.66--2.41     0.476     fixed      0               0.573
   ≥10%                       6             1.90     1.45--2.49    \<0.001    fixed    19.4              0.287
  Follow up (month)                                                                           
   \<60                       7             1.59     1.38--1.84    \<0.001    fixed      0               0.633
   ≥60                        3             1.93     1.22--3.03     0.005     fixed    52.5              0.122
  DFS                         Ethnicity                                                       
   Caucasian                  4             2.63     1.73--4.01    \<0.001    fixed    15.1              0.316
   Asian                      2             2.38     1.18--4.80     0.015     fixed      0               0.778
  Tumor extent                                                                                
   all-stage                  1             2.11     0.74--6.50     0.178       ─        ─                 ─
   localized                  5             2.63     1.79--3.85    \<0.001    fixed      0               0.473
   metastatic                 0               ─           ─           ─         ─        ─                 ─
  Histopathological subtype                                                                   
   ccRCC                      3             3.66     2.00--6.72    \<0.001    fixed      0               0.463
  Counting method                                                                             
   eyeball counting           5             2.57     1.73--3.79    \<0.001    fixed      0               0.452
   formal counting            0               ─           ─           ─         ─        ─                 ─
  Cutoff of staining                                                                          
   \<10%                      1             7.18     1.91--26.99    0.004       ─        ─                 ─
   ≥10%                       5             2.36     1.62--3.43    \<0.001    fixed      0               0.884
  Follow up (month)                                                                           
   \<60                       3             2.45     1.54--3.91    \<0.001    fixed      0               0.653
   ≥60                        3             2.73     1.55--4.82     0.001     fixed    26.9              0.255

OS: overall survival; CSS: cancer-specific survival; DFS: disease-free survival; HR: hazard ratio; CI: confidence interval; RCC: renal cell carcinoma; ccRCC: clear cell renal cell carcinoma.

###### Meta-analysis of the association between high Ki-67 expression and clinicopathological features of RCC.

  Variables                          Studies   Pooled RR     95% CI     P Value   Model    Heterogeneity *I*^*2*^ (%)   P Value
  --------------------------------- --------- ----------- ------------ --------- -------- ---------------------------- ---------
  TNM stage (III/IV vs. I/II)           4        2.03      1.68--2.44   \<0.001   fixed               18.2               0.300
  pT stage (T3/T4 vs. T1/T2)            8        1.67      1.35--2.06   \<0.001   random              58.5               0.018
  Metastasis^a^ (yes vs. no)            5        2.15      1.77--2.62   \<0.001   fixed               15.9               0.313
  Fuhrman grade (III/IV vs. I/II)       8        1.77      1.20--2.60    0.004    random              95.2              \<0.001

^a^Both lymph node and distant metastases; RR: relative ratio; CI: confidence interval; RCC: renal cell carcinoma.

[^1]: These authors contributed equally to this work.
